Patents by Inventor Zhenrong Xu

Zhenrong Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for treating Huntington's disease
    Patent number: 12384789
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: April 18, 2022
    Date of Patent: August 12, 2025
    Assignee: PTC Therapeutics, Inc.
    Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
  • Penicillin-binding protein inhibitors
    Patent number: 12173018
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: December 24, 2024
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Jodie Hamrick, Steven A. Boyd, Allison L Zulli, Eugen F. Mesaros, Stephen M. Condon, Robert E. Lee Trout, Cullen L. Myers, Zhenrong Xu
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20240270762
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: March 25, 2022
    Publication date: August 15, 2024
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Steven A. BOYD, Allison L. ZULLI, Stephen M. CONDON, Cullen L. MYERS, Zhenrong XU, Tsuyoshi UEHARA, Nathan LINE
  • COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20230331725
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
  • Compounds for treating Huntington's disease
    Patent number: 11780839
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 10, 2023
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20230114728
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 13, 2023
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Steven A. BOYD, Allison L. ZULLI, Stephen M. CONDON, Cullen L. MYERS, Zhenrong XU, Tsuyoshi Uehara, Nathan LINE
  • COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20220251098
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 11, 2022
    Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
  • Compounds for treating Huntington's disease
    Patent number: 11407753
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: August 9, 2022
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20210198288
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 1, 2021
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Steven A. BOYD, Allison L. ZULLI, Eugen F. MESAROS, Stephen M. CONDON, Robert E. Lee TROUT, Cullen L. MYERS, Zhenrong XU
  • Modulators of ROR-gamma
    Patent number: 11008340
    Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 18, 2021
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
  • COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20210024525
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 28, 2021
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
  • COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20200165256
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: June 5, 2018
    Publication date: May 28, 2020
    Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
  • Purine derivatives as CD73 inhibitors for the treatment of cancer
    Patent number: 10654884
    Abstract: Provided are novel purine nucleoside/nucleotide analogues compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: May 19, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Salvacion Cacatian, David A. Claremon, Lanqi Jia, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Yajun Zheng
  • MODULATORS OF ROR-GAMMA
    Publication number: 20190322687
    Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Application
    Filed: November 17, 2016
    Publication date: October 24, 2019
    Applicant: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
  • Inhibitors of beta-secretase
    Patent number: 10336717
    Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: July 2, 2019
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian McKeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
  • INHIBITORS OF BETA-SECRETASE
    Publication number: 20180344734
    Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.
    Type: Application
    Filed: March 12, 2018
    Publication date: December 6, 2018
    Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresch B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast
  • Inhibitors of beta-secretase
    Patent number: 9949975
    Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: April 24, 2018
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast
  • INHIBITORS OF BETA-SECRETASE
    Publication number: 20170196867
    Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.
    Type: Application
    Filed: December 19, 2016
    Publication date: July 13, 2017
    Applicant: Vitae Pharmaceuticals, Inc.
    Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast
  • PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20170044203
    Abstract: Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
    Type: Application
    Filed: April 23, 2015
    Publication date: February 16, 2017
    Inventors: Salvacion Cacatian, David A. Claremon, Lanqi Jia, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Yajun Zheng
  • Inhibitors of beta-secretase
    Patent number: 9526727
    Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: December 27, 2016
    Assignee: Vitae Pharmaceutical, Inc.
    Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast